Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Liabilities (2020 - 2023)

Candel Therapeutics' Total Liabilities history spans 4 years, with the latest figure at $27.0 million for Q3 2023.

  • For Q3 2023, Total Liabilities fell 17.76% year-over-year to $27.0 million; the TTM value through Sep 2023 reached $27.0 million, down 17.76%, while the annual FY2022 figure was $30.0 million, 19.58% up from the prior year.
  • Total Liabilities for Q3 2023 was $27.0 million at Candel Therapeutics, down from $27.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $37.8 million in Q1 2022 and bottomed at $12.3 million in Q2 2020.
  • The 4-year median for Total Liabilities is $27.5 million (2021), against an average of $26.2 million.
  • The largest annual shift saw Total Liabilities soared 122.55% in 2021 before it dropped 27.02% in 2023.
  • A 4-year view of Total Liabilities shows it stood at $12.8 million in 2020, then soared by 96.09% to $25.1 million in 2021, then rose by 19.58% to $30.0 million in 2022, then fell by 9.8% to $27.0 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Total Liabilities are $27.0 million (Q3 2023), $27.9 million (Q2 2023), and $27.6 million (Q1 2023).